Naproxen: Propionic-Acid NSAID, Analgesia, Inflammation and Risk Reduction

Evidence-informed pharmacology monograph updated 10 November 2026. Educational material; individualized treatment requires clinical assessment and current local prescribing information.

Overview and pharmacology

Naproxen is a nonselective COX-inhibiting arylpropionic acid NSAID available in prescription and selected OTC formulations. It reduces pain, inflammation and fever, including in osteoarthritis, inflammatory arthritis, dysmenorrhea, tendinitis and acute gout. It treats symptoms but is not disease-modifying treatment for rheumatoid arthritis [1,2].

Mechanism and kinetics

Inhibition of both COX-1 and COX-2 reduces prostaglandins and thromboxane, yielding analgesic and anti-inflammatory effects but exposing patients to GI bleeding, impaired platelet function and renal ischemia risk. Naproxen is well absorbed, strongly albumin bound and has a relatively long elimination half-life, commonly about 12–17 hours, supporting less frequent dosing than some NSAIDs. Hepatic metabolism and renal excretion influence drug exposure [1].

Formulations are not interchangeable

Naproxen base, naproxen sodium and enteric/delayed-release preparations differ in salt composition, onset and delivery. Rapid-release sodium products may be more suitable for time-sensitive pain than delayed-release formulations. Dosing should use the specific product and indication; a tablet strength in naproxen base is not identical to an equal mass of naproxen sodium [1,2].

Clinical applications

Naproxen may relieve acute musculoskeletal pain, arthritis symptoms, menstrual pain and acute gout attacks; topical or nonpharmacologic options may be safer for some localized problems. For longer use, periodically reassess clinical benefit, blood pressure, edema, kidney function and GI symptoms. Considering gastroprotection in patients at elevated GI risk can reduce ulcer risk, but does not eliminate all bleeding or cardiovascular harms [1,2].

Major harms and boxed warnings

Like all systemic nonaspirin NSAIDs, naproxen carries boxed warnings for potentially fatal cardiovascular thrombotic events and gastrointestinal ulceration, bleeding or perforation. Some comparative studies suggest a relatively favorable thrombotic profile compared with certain NSAIDs, but naproxen is not cardiovascular-risk free. It is contraindicated in the setting of coronary artery bypass surgery, and serious aspirin-sensitive asthma or NSAID allergy warrants avoidance [2].

Renal, pregnancy and interacting drugs

NSAIDs may precipitate AKI in older, dehydrated, heart-failure or CKD patients, particularly with an ACEi/ARB plus diuretic. With anticoagulants, antiplatelets, glucocorticoids or SSRIs, bleeding risk may increase. NSAID pregnancy warnings include oligohydramnios/fetal renal effects at about 20 weeks or later and premature fetal ductus closure at about 30 weeks or later. Select the lowest effective dose for the shortest necessary duration [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Naproxen tablets: US prescribing information, revised September 2026. Available from: https://www.dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=e519fa49-5bd9-405c-a7fb-1403edb8976b&type=pdf
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *